Related Experiment Video
Updated: Sep 28, 2026
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer Achieving
Yosuke Nakanishi1, Yohei Kawashima1, Masanao Shinohara1
1Department of Urology Ageo Central General Hospital Ageo Japan.
Introduction:
Enfortumab vedotin plus pembrolizumab has emerged as a standard first-line therapy for advanced urothelial carcinoma (UC). However, pseudoprogression during this combination remains poorly characterized.
Case Presentation:
A 71-year-old man with muscle-invasive bladder cancer and lymph node metastasis received enfortumab vedotin plus pembrolizumab. During treatment, imaging suggested tumor progression with new hydronephrosis. Repeat transurethral resection revealed no viable tumor. Because of persistent symptoms, robot-assisted radical cystectomy was performed. Histopathological examination demonstrated no residual tumor cells, indicating pathological complete response (ypT0N0), with prominent CD8- and CD4-positive T-cell infiltration and minimal CD20-positive B-cell infiltration.
Conclusion:
This case suggests that pseudoprogression may occur during enfortumab vedotin plus pembrolizumab therapy. Careful interpretation of radiological findings is essential to avoid premature treatment discontinuation.